All Insight, Analysis and Views

Physician Views Preview: Will docs limit Aduhelm use to beta-amyloid Alzheimer's patients?

Ref: Physician Views Desk

Tags: Physician Views Biogen Dementia Medical Affairs Regulatory Affairs Aduhelm aducanumab

ViewPoints: Vertex hopes third time’s the charm in AATD

Ref: ViewPoints Desk

Tags: ViewPoints Vertex Clinical Research (R&D) Corporate Affairs VX-864 VX-814

The FirstTake Podcast – FirstWord’s editors discuss the controversial approval of Biogen’s Aduhelm

Ref: ViewPoints Desk

Tags: ViewPoints Biogen EQRx Dementia Lung Cancer Clinical Research (R&D) Corporate Affairs Regulatory Affairs Aduhelm aducanumab

Friday Five – The Pharma Week in Review (11 June 2021)

Ref: Friday Five Desk

Tags: Friday Five Clinical Research (R&D) Marketing & Sales Medical Affairs Regulatory Affairs

ViewPoints: Akero, Arbutus lead upcoming EASL expectations

Ref: ViewPoints Desk

Tags: ViewPoints Akero Therapeutics Arbutus Biopharma Madrigal Pharmaceuticals Assembly Biosciences Arrowhead Gilead Nonalcoholic steatohepatitis Hepatitis Clinical Research (R&D)

ASCO 2021 Physician Views Results: Lynparza set to play a key role in adjuvant BRCAm breast cancer

Ref: Physician Views Desk

Tags: Physician Views Poll Results AstraZeneca Merck & Co.Breast Cancer Clinical Research (R&D) Medical Affairs ASCO Lynparza

Physician Views Results: Alzheimer's docs split on whether the FDA was right to approve Aduhelm

Ref: Physician Views Desk

Tags: Physician Views Poll Results Biogen Eisai Dementia FDA Clinical Research (R&D) Medical Affairs Regulatory Affairs aducanumab Aduhelm

ViewPoints: argenx optimistic in the face of J&J rejection

Ref: ViewPoints Desk

Tags: ViewPoints arGEN-X J&J Leukaemias Corporate Affairs Licensing cusatuzumab

ViewPoints: Will Biogen’s attempt to shift debate on Aduhelm pay off?

Ref: ViewPoints Desk

Tags: ViewPoints Biogen Eisai Lilly Roche Dementia FDA Corporate Affairs Marketing & Sales Medical Affairs Aduhelm

ASCO 2021 Physician Views Results: Novartis’ Lu-PSMA-617 backed as a useful new treatment option for prostate cancer

Ref: Physician Views Desk

Tags: Physician Views Poll Results Novartis Prostate Cancer Clinical Research (R&D) Medical Affairs ASCO Lu-PSMA-617